Baxter restructures licensing deal with Xenetic Biosciences

Baxter International has restructured its agreement with Xenetic Biosciences for the development of BAX 826, a recombinant Factor VIII treatment for haemophilia A, and also made a $10m investment in Xenetic.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news